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TO THE EDITORCoronary Occlusion and
Ischemia ReductionI read with great interest the article by Jang et al. (1)
and the accompanying editorial by Barbato and
Wijns (2) regarding the long-term survival beneﬁt of
revascularization compared with medical therapy in
patients with coronary chronic total occlusion and
well-developed collateral circulation. According to
the authors, it seems as though all patients received
“modern medical therapy,” and because this was a
retrospective study, there was no requirement for
informed consent.
I congratulate the authors for a very nice piece of
work, but I would like to remind them that the term
they use (CTO), standing for chronic “total” occlu-
sion, might instead be abbreviated CCO, standing for
chronic coronary occlusion. “Total” is redundant
because all occlusions are total.
Several years ago, I wrote an article on coronary
artery collaterals (3). Before and since writing that
article, I have always believed that collaterals do not
appear angiographically unless ischemia is present in
the distribution of those collaterals. I have also never
believed that if the collateral provides excellent blood
ﬂow to the ischemic zone, ischemia will disappear
and the collaterals will remain. To put it somewhat
differently, in my opinion, visible collaterals only
exist if ischemia is present, and if ischemia is present,
the myocardium supplied by the collateral vessel is
viable.
All collateral seen angiographically may be pro-
tective against or limit infarction but may not provide
adequate ﬂow to prevent myocardial ischemia and
regional myocardial dysfunction. Thus, I do not
believe that all angiographically visible collaterals
eliminate myocardial ischemia, but they may make
ischemia more difﬁcult to provoke.
I could not ﬁnd out whether or not the patients
evaluated in this paper (1) had post-percutaneous
coronary intervention (PCI) angiography to deter-
mine the presence or absence of collaterals after the
revascularization was accomplished. This would have
been an important observation that would indicatethat collaterals are only present when the demand
(ischemia) for them is present.
The conclusion that the authors make, that
“aggressive revascularization by surgery or PCI
may reduce the risk of mortality and MACE [major
adverse cardiac events] by eliminating ‘ischemia’,”
seems reasonable to me, but I would also propose that
the risk of mortality and MACE may be reduced
if “ischemia” is eliminated by aggressive medical
therapy. In fact, I cannot think of a single incidence in
which the continued presence of ischemia is good for
the patient.*C. Richard Conti, MD
*Medicine
7900 SW 43rd Drive
Gainesville, Florida 32608
E-mail: richard.conti@medicine.uﬂ.edu
http://dx.doi.org/10.1016/j.jcin.2015.03.021
Please note: Dr. Conti has reported that he has no relationships relevant to the
contents of this paper to disclose.
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3. Conti CR. Coronary artery collaterals. Clin Cardiol 2010;33:188–9.REPLY: Coronary Occlusion andIschemia ReductionMy colleagues and I appreciated the comments of
Professor Conti regarding the clinical signiﬁcance of
revascularization for the treatment of coronary
chronic total occlusion (CTO) with well-developed
collateral circulation. We read with interest the
editorial comment provided by Barbato and Wijns (1)
in addition to the letter to the editor by Conti. It is an
undeniable fact that successful revascularization of
CTO is associated with a survival beneﬁt, but the
greatest challenge of this aggressive CTO treatment is
the low predictability of successful revascularization
and the relatively high possibility of fatal complica-
tions. In this sense, we agree with Barbato and Wijns’
opinion that accurate risk stratiﬁcation and better
selection criteria for patients undergoing CTO
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1130revascularization are needed. We also agree with
Conti’s opinion that, unless ischemia is present, col-
laterals do not appear angiographically; if the collat-
eral provides excellent blood ﬂow to ischemic
myocardium, the collaterals will remain (2). Werner et
al. (3) reported that even collaterals that appear well
developed on angiography are not able to fully
replace anterograde blood ﬂow; therefore, restoring
ﬂow reserve does little to prevent myocardial
ischemia. Our hypothesis was that well-developed
collateral ﬂow in patients with stable CTO lesions
may partially protect the myocardium and the
revascularization may allow complete maintenance
of viable myocardium (4), and we identiﬁed long-
term survival beneﬁts of aggressive revasculariza-
tion compared with medical therapy in our study.
Unfortunately, because we did not routinely per-
form contralateral injections after successful re-
vascularization of CTO in our practice, we could not
identify the existence or disappearance of collaterals
after CTO revascularization, as mentioned in Conti’s
letter. However, we agree with his hypothesis that
the change of collateral ﬂow after CTO revasculari-
zation in coronary angiography might correlate
with whether ischemia of viable myocardium occurs
or not. This hypothesis requires further detailed
study.
As stated by Barbato and Wijns (1), our study
might have reported a higher rate of successful
percutaneous coronary intervention (PCI) or coronary
bypass grafting (CABG) compared to previous studies
of CTO revascularization. However, remarkable
developments in the survival beneﬁts posed by CTO
revascularization are rapidly becoming a reality
because CTO PCI techniques have improved and the
experience of CABG has also increased. We anticipate
that the survival beneﬁts of aggressive reduction of
remnant ischemia by revascularization or intensive
medication in patients with CTO lesions will be veri-
ﬁed by future large-scale randomized trials.Woo Jin Jang, MD
Jeong Hoon Yang, MD, PhD
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Fate of Bioresorbable
Vascular Scaffold Metallic
Radio-Opaque Markers at
the Site of Implantation
After BioresorptionThe use of bioresorbable vascular scaffolds (BRS) is
increasing in patients with coronary artery disease
undergoing percutaneous coronary interventions.
Because the devices are radiolucent on ﬂuoroscopy,
2 adjacent cylindrical platinum markers are incor-
porated in the proximal and distal edges of the
polymeric devices for precise scaffold deployment
and post-dilation during the procedure. In addition,
the metallic radio-opaque markers (MRMs) also
provide anatomic landmarks for long-term follow-up
when all the polymeric struts have been bioresorbed.
There has been concern about the potential risk of
MRM beads becoming dislodged from the device and
embolized into the coronary bed after complete
bioresorption of the polymeric struts. Beyond the
biological hazard of MRMs embolization, the addi-
tional inconvenience is that the embolization may
result in the incapacity to locate the coronary
segment where the fully bioresorbed scaffold was
implanted. Invasive assessment of BRS such as
quantitative coronary angiography (QCA), intravas-
cular ultrasound (IVUS), or optical coherence to-
mography (OCT) may be unable to detect the precise
location of the MRMs either because of the
